Humacyte’s (HUMA) “Buy” Rating Reaffirmed at HC Wainwright

HC Wainwright restated their buy rating on shares of Humacyte (NASDAQ:HUMA) in a research report released on Wednesday morning,Benzinga reports. The firm currently has a $12.00 target price on the stock. HC Wainwright also issued estimates for Humacyte’s FY2024 earnings at ($1.36) EPS and FY2025 earnings at ($0.77) EPS.

Other analysts have also issued research reports about the stock. BTIG Research reiterated a “buy” rating and issued a $10.00 price objective on shares of Humacyte in a research note on Friday, October 18th. EF Hutton Acquisition Co. I upgraded shares of Humacyte to a “strong-buy” rating in a research report on Monday, September 9th. TD Cowen restated a “buy” rating and set a $10.00 price target on shares of Humacyte in a research report on Friday, October 18th. Piper Sandler set a $6.00 price target on shares of Humacyte and gave the company a “neutral” rating in a research report on Friday, October 18th. Finally, Benchmark restated a “buy” rating and set a $15.00 price target on shares of Humacyte in a research report on Thursday, October 10th. One analyst has rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus target price of $11.00.

Humacyte Price Performance

NASDAQ:HUMA opened at $4.84 on Wednesday. The firm has a market capitalization of $577.06 million, a P/E ratio of -3.61 and a beta of 1.47. Humacyte has a 1-year low of $2.35 and a 1-year high of $9.97. The company’s fifty day moving average price is $5.42 and its 200-day moving average price is $6.17. The company has a debt-to-equity ratio of 0.61, a current ratio of 1.10 and a quick ratio of 5.41.

Insider Activity

In other news, Director Brady W. Dougan sold 252,676 shares of the firm’s stock in a transaction dated Tuesday, August 27th. The shares were sold at an average price of $6.71, for a total value of $1,695,455.96. Following the transaction, the director now directly owns 4,306,464 shares of the company’s stock, valued at approximately $28,896,373.44. This trade represents a 5.54 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, CFO Dale A. Sander sold 39,389 shares of the firm’s stock in a transaction dated Tuesday, August 27th. The stock was sold at an average price of $6.68, for a total transaction of $263,118.52. Following the completion of the transaction, the chief financial officer now directly owns 2,000 shares in the company, valued at approximately $13,360. This represents a 95.17 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 1,084,153 shares of company stock worth $6,869,996 over the last 90 days. 11.20% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Humacyte

Several hedge funds and other institutional investors have recently modified their holdings of the business. Endowment Wealth Management Inc. lifted its stake in shares of Humacyte by 3.1% in the second quarter. Endowment Wealth Management Inc. now owns 100,518 shares of the company’s stock worth $482,000 after buying an additional 3,000 shares in the last quarter. nVerses Capital LLC purchased a new position in Humacyte during the second quarter worth about $28,000. Private Advisor Group LLC raised its stake in Humacyte by 1.8% during the third quarter. Private Advisor Group LLC now owns 373,110 shares of the company’s stock worth $2,030,000 after purchasing an additional 6,510 shares during the period. The Manufacturers Life Insurance Company raised its stake in Humacyte by 32.5% during the second quarter. The Manufacturers Life Insurance Company now owns 34,919 shares of the company’s stock worth $168,000 after purchasing an additional 8,557 shares during the period. Finally, China Universal Asset Management Co. Ltd. raised its stake in Humacyte by 64.1% during the third quarter. China Universal Asset Management Co. Ltd. now owns 22,955 shares of the company’s stock worth $125,000 after purchasing an additional 8,965 shares during the period. 44.71% of the stock is owned by hedge funds and other institutional investors.

About Humacyte

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.